Endologix Inc. said Thursday the U.S. Food and Drug Administration has approved its expanded collection of stent graft products.
The medical device company said the approval covers 31 new sizes of its "Powerlink" stent graft products, which should expand the number of patients they can be used in by 5 percent to 10 percent.
Stent grafts reinforce a ruptured or a ballooning section of an artery.
The Powerlink line treats abdominal aortic aneurysms, or weakening in the wall of the aorta, the largest artery in the body, which extends from the chest to the abdomen.
Endologix said it will move ahead with a limited release this month and a full market release in the fourth quarter.
The company's stock rose 3 cents to $4.29 in afternoon trading.